Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome

被引：10
|
作者：
Komrokji, Rami S. [1 ]
Singh, Avani M. [2 ,3 ]
Al Ali, Najla [1 ]
Chan, Onyee [1 ]
Padron, Eric [1 ]
Sweet, Kendra [1 ]
Kuykendall, Andrew [1 ]
Lancet, Jeffrey E. [1 ]
Sallman, David A. [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA
[2] Univ S Florida, Dept Hematol Oncol, Tampa, FL 33620 USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
BLOOD CANCER JOURNAL | 2022年 / 12卷 / 11期
关键词：
D O I：
10.1038/s41408-022-00744-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents
    Komrokji, Rami S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S56 - S59
  • [22] Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome- a Multicenter Retrospective Analysis
    Murthy, Guru Subramanian Guru
    Ball, Somedeb
    Feld, Jonathan
    Abboud, Ramzi
    Haddadin, Michael
    Patel, Shyam Ajay
    Kishtagari, Ashwin
    Hawkins, Hayley
    Guerra, Veronica
    Dworkin, Emily
    Tawfiq, Reema K.
    Dulak, Dominika
    Feng, Amber
    Winer, Eric S.
    Foucar, Charles
    Abaza, Yasmin
    Shallis, Rory M.
    Lin, Chenyu
    Badar, Talha
    Cotte, Christina
    Patel, Anand Ashwin
    Balasubramanian, Suresh Kumar
    Shukla, Asmita
    Cohen-Nowak, Adam
    Im, Annie
    Szabo, Aniko
    Atallah, Ehab L.
    BLOOD, 2024, 144 : 3206 - 3207
  • [23] Making the most of hypomethylating agents in myelodysplastic syndrome
    Bhatt, Geetika
    Blum, William
    CURRENT OPINION IN HEMATOLOGY, 2017, 24 (02) : 79 - 88
  • [24] A Phase I Study of the Combination of Venetoclax and Azacitidine in Relapse/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
    Desikan, Sai Prasad Prasad
    Montalban-Bravo, Guillermo
    Ohanian, Maro
    Daver, Naval
    Yilmaz, Musa
    Konopleva, Marina
    Kadia, Tapan M.
    Venugopal, Sangeetha
    Schneider, Heather
    Chien, Kelly S.
    Kanagal-Shamanna, Rashmi
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    BLOOD, 2021, 138 : 3704 - +
  • [25] Transplantation for myelodysplastic syndrome in the era of hypomethylating agents
    Gerds, Aaron T.
    Deeg, H. Joachim
    CURRENT OPINION IN HEMATOLOGY, 2012, 19 (02) : 71 - 75
  • [26] Azacitidine and Venetoclax Combination for Upfront Treatment of Higher-Risk Myelodysplastic Syndromes
    Al Ali, Najla
    Sallman, David
    Chan, Onyee
    Padron, Eric
    Sweet, Kendra
    Kuykendall, Andrew
    Lancet, Jeffrey
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S341 - S341
  • [27] The Direct Medical Costs of Treatment Discontinuation Among Higher-Risk Myelodysplastic Syndrome Patients Receiving Hypomethylating Agents
    Joshi, Namita
    Kale, Hrishikesh P.
    Corman, Shelby
    Hill, Kala
    Wert, Tim
    Zeidan, Amer M.
    BLOOD, 2020, 136
  • [28] Integrating advanced analytical methods to assess epigenetic marks affecting response to hypomethylating agents in higher risk myelodysplastic syndrome
    Nikolopoulos, Theodoros
    Bochalis, Eleftherios
    Chatzilygeroudi, Theodora
    Chondrou, Vasiliki
    Dereki, Irene
    Athanasopoulou, Katerina
    Zafeiropoulos, John
    Bourikas, Kyriakos
    Patrinos, George P.
    Symeonidis, Argiris
    Sgourou, Argyro
    MOLECULAR MEDICINE, 2025, 31 (01)
  • [29] Morphologic Changes in Myelodysplastic Syndrome Treated with Hypomethylating Agents
    Rathke, S. K.
    Olteanu, H.
    Kroft, S. H.
    Harrington, A. M.
    MODERN PATHOLOGY, 2012, 25 : 364A - 364A
  • [30] Morphologic Changes in Myelodysplastic Syndrome Treated with Hypomethylating Agents
    Rathke, S. K.
    Olteanu, H.
    Kroft, S. H.
    Harrington, A. M.
    LABORATORY INVESTIGATION, 2012, 92 : 364A - 364A
12345